Drugs / hexavalent reassortant rotavirus attenuated live vaccine
hexavalent reassortant rotavirus attenuated live vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06967272 | Jan 2025 → Jun 2026 overdue | Rotavirus infection | Sinovac Life Sciences Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | hexavalent reassortant rotavirus attenuated live vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06967272 ↗ |
| Modality | Vaccine | “The investigational vaccine is available in both high-dose and low-dose formulations.” NCT06967272 ↗ |
| Route | Oral | “Oral hexavalent reassortant rotavirus attenuated live vaccine (low-dose) three doses administered orally” NCT06967272 ↗ |